Comparative study in man of the absorption and excretion of amobarbital-14C from sustained-release and nonsustained-release dosage forms

Rosen, Earl; Polk, Andrew; Free, Spencer M.; Tannenbaum, Philip J.; Crosley, Archer P.

doi:10.1002/jps.2600561014

Cited by 7 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to eliminate production complexity associated with the manufacture of mixed release granules, formulations were designed to produce granules with uniform rather than mixed release characteristics. Delayed release ascorbic acid consisting of ascorbic acid crystals encapsulated in partially hydrogenated cottonseed oil has been marketed for the food industry [19][20][21].…”

Section: Models Based On Dissolutionmentioning

confidence: 99%

Design of Sustained Action Dosage Forms; Mini-Review

Abdellatif¹

2018

Pharm Anal Acta

View full text Add to dashboard Cite

Greatest idealized per-oral sustained action products have been formulated in the form of oral dosage forms such as capsules or tablets. The characteristic trouble of preparing sustained action liquids has controlled the availability of such dosage forms. Encapsulated long-acting dosage forms have two particular benefits over capsules and tablet designs. Firstly, the inability to be disintegrated which may persist in the stomach for long periods of time, extremely suspending in the stomach and retard the absorption of maintenance dose. Secondly, the disintegration of the capsule shell in the gastric fluid releases particles that pass across the pyloric valve. Also, the release of drug by a meaningful fraction of the granules is highly possible. If a tablet fails to release drug, the entire maintenance dose is lost. This review discusses the different methods for enhancing the sustained drug action. cancer cells, such as the SSTRs, the folate receptor, and transferrin receptors. Moreover, nanoparticles coated cell-penetrating peptides and protein-transduction domains, such as oligoarginine and TAT facilitated the uptake of these nanoparticles which cannot successfully enter cancer cells [8]. This review discusses the different methods for enhancing the sustained drug action, the barrier principle, model based on diffusion, and model based on dissolution. Moreover, the review discusses the principle release from the matrix.

show abstract

Section: Models Based On Dissolutionmentioning

confidence: 99%

Design of Sustained Action Dosage Forms; Mini-Review

Abdellatif¹

2018

Pharm Anal Acta

View full text Add to dashboard Cite

show abstract

“…A variety of slowly dissolving coatings are available, such as those based on various combinations of carbohydrate sugars and cellulose, polyethylene glycol, polymeric materials, and wax. An illustration of this approach is given by Rosen et al [36], who described the release of amobarbital and dextroamphetamine from sustained release dosage forms employing wax-coated granules. The rate of drug release was found to decrease progressively as the percentage of wax in the coating increases.…”

Section: Models Based On Dissolutionmentioning

confidence: 99%

Microparticles Formulation as a Targeting Drug Delivery System

Abdellatif¹

2017

JNMR

View full text Add to dashboard Cite

A great interest has been centered on the idea of replacing daily administration of a drug with delivery devices which release a constant effective dose to the target tissues via a controlled release mechanism. Many pharmaceutical investigations have been carried out to develop controlled release oral dosage forms that sustain drug release. A sustained release system is defined as one in which the drug is initially made available to the body in an amount sufficient to give a rapid onset of the desired therapeutic response, after which the level of the therapeutic concentration is maintained constant for the desired duration of time. This review discusses the formulation of sustained release drugs by different kinds of microparticles as a targeting tool for new drug delivery.

show abstract